STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation	Page No/ Line No	Section and Paragraph
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Page 2/Lines 50-51	Abstract P 1
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2/Lines 57-77	Abstract P 2-4
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4/Lines 90-118	Introduction P 1-3
Objectives	3	State specific objectives, including any prespecified hypotheses	Pg 4/Lines 122-126	Introduction P3
Methods				
Study design	4	Present key elements of study design early in the paper	Pg 5/Lines 128-155	Methods P 1-3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pg 5-6/Lines 128-155	Methods P 1-3
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	Pg 5-6/Lines 129-137	Methods P1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pg 7/Lines 157-186	Methods P 4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pg 6-7/Lines 152-186	Methods P 3-6
Bias	9	Describe any efforts to address potential sources of bias	Pg 6/Lines 143-144	Methods P 2
Study size	10	Explain how the study size was arrived at	Pg 5/Lines 131-136	Methods P 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Pg 7-8/Lines 175-186	Methods P 6
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	Pg 10/Lines 205-224	Methods P 9-11
		(*b*) Describe any methods used to examine subgroups and interactions	Pg 8/Lines 188-203	Methods P 7-8
		(*c*) Explain how missing data were addressed	Pg 9/Lines 214-215	Methods P 10
		(*d*) If applicable, describe analytical methods taking account of sampling strategy	Pg 8/Lines 188-203	Methods P 7-8
		(*e*) Describe any sensitivity analyses	N/A**	N/A**
Results				

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Pg 10/Lines 227-230	Results P 1
		(b) Give reasons for non-participation at each stage	N/A**	N/A**
		(c) Consider use of a flow diagram	N/A**	N/A**
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Pg 10/Lines 227-232	Results P 1
		(b) Indicate number of participants with missing data for each variable of interest	Pg 9/Lines 214-215	Methods P 10
Outcome data	15*	Report numbers of outcome events or summary measures	Pg 11-12/Lines 254-279	Results P 4-6
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Pg 11-12/Lines 254-279	Results P 4-8
		(*b*) Report category boundaries when continuous variables were categorized	N/A**	N/A**
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A**	N/A**
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Pg 10-11/Lines 234-251	Results P 2-3
Discussion				
Key results	18	Summarise key results with reference to study objectives	Pg 14/Lines 310-317	Discussion P 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pg 17/Lines 386-397	Discussion P 9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pg 14-17/Lines 319-384	Discussion P 2-8
Generalisability	21	Discuss the generalisability (external validity) of the study results	Pg 18/Lines 396-397	Discussion P 9
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Pg 19/Lines 430-433	Conflicts P 1

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

****N/A explanations**

12e) Not relevant in our analyses

13c) Participation flow diagram was included in previously published analysis of present cohort and is referenced in-text.

16b) No continuous variables were used for analyses, positivity thresholds for included assays are included in the methods section and these guidelines are used throughout except as described in Results

16c) Not relevant for our analyses.

Article information: https://dx.doi.org/10.21037/jlpm-22-19

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.